From Scott Losermann's latest document.
"Moreover, although FDA approved Jakafi in 2019 for treatment of SR-aGVHD in adult
and pediatric patients 12 years and older based primarily upon the results of a pivotal, single-arm
clinical trial, this precedent cannot be applied to remestemcel-L. FDA accepted the results from
the single-arm clinical trial as the sole basis of efficacy only after considering several regulatory
factors regarding SR-aGVHD and prior clinical experience with Jakafi. Specifically, the FDA
reviewers explained that such reliance was appropriate “where the disease is life-threatening, there
are no approved therapies and no optimal therapy identified, the efficacy endpoint is objective, the
activity of the drug is established in other diseases, and there is a substantial safety database ….”27
Significantly, several of these factors clearly do not apply to remestemcel-L."
I agree to now get rid of Jakafi and replace it with a better efficacious treatment. Great suggestion Scott!!
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-5475
-
- There are more pages in this discussion • 12,346 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 539 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.12 | 10643 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 452 | 1.215 |
2 | 539 | 1.190 |
2 | 657 | 1.180 |
1 | 20000 | 1.170 |
4 | 14659 | 1.165 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 8788 | 2 |
1.145 | 1000 | 1 |
1.150 | 10000 | 1 |
1.160 | 24152 | 5 |
1.165 | 2100 | 2 |
Last trade - 09.51am 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online